Timothy J Corey, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 400 Route 17 South, Ridgewood, NJ 07450 Phone: 201-652-4536 Fax: 201-652-4906 |
Paige Applebaum-farkas, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1200 East Ridgewood Avenue, Ridgewood, NJ 07450 Phone: 201-493-1717 Fax: 201-493-1009 |
Tamar Zapolanski, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1200 E Ridgewood Ave Ste 302e, Ridgewood, NJ 07450 Phone: 201-689-2103 |
Dr. Iris H Kopeloff, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 1200 E Ridgewood Ave, Suite 107, Ridgewood, NJ 07450 Phone: 201-689-2103 Fax: 201-689-2108 |
Karin H Satra, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 400 Route 17 South, Ridgewood, NJ 07450 Phone: 201-652-4536 Fax: 201-652-4906 |
Hirshel Kahn, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1200 E Ridgewood Ave, Ridgewood, NJ 07450 Phone: 201-493-1717 Fax: 201-493-1009 |
Margaret Fonder, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 400 Route 17 Ste 2, Ridgewood, NJ 07450 Phone: 201-652-4536 Fax: 201-652-4906 |
News Archive
The Joint Center for Political and Economic Studies Health Policy Institute will unveil a study "Following the Money: Tracking Federal AIDS Appropriations to Address Disparities in HIV and AIDS Treatment in the United States." The study looks at funds and resources provided under the Ryan White Act and concludes that the allocation does not adequately address the needs of the minority AIDS community and fails to reflect the rapid rise in AIDS infection rates in rural, Southern communities, which are primarily African American communities.
In this interview, News-Medical talks to Dr. Irma Börcsök (CEO of PromoCell) and Dörte Keimer (Head of Quality Assurance) about PromoCell, the work they do and the latest GMP certification the company has achieved - EXCiPACT.
Researchers have found that biomass compensation may impair the health of populations that depend on fish for their daily nutritional intake.
Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.
The January - December period and fourth quarter 2010 in brief
› Verified 9 days ago